GSK-3β-induced Tau pathology drives hippocampal neuronal cell death in Huntington's disease: Involvement of astrocyte-neuron interactions

Cell Death and Disease

Volumn 7, Issue 4, 2016, Pages

  L'Episcopo, F ^a,b   Drouin Ouellet, J ^c   Tirolo, C ^a   Pulvirenti, A ^d   Giugno, R ^a   Testa, N ^a   Caniglia, S ^a   Serapide, M F ^b   Cisbani, G ^e   Barker, R A ^c,f   Cicchetti, F ^e,g   Marchetti, B ^a,b  

^a OASI RESEARCH INSTITUTE IRCCS   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c LUND UNIVERSITY   (Sweden)

^d UNIVERSITY OF CATANIA   (Italy)

^e University Laval   (Canada)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 METHOXYBENZYL) 3 (5 NITRO 2 THIAZOLYL)UREA; CASPASE 3; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; INTERLEUKIN 6; MESSENGER RNA; REACTIVE NITROGEN SPECIES; TAU PROTEIN; TUMOR NECROSIS FACTOR; CYTOKINE; ISOPROTEIN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASTROCYTE; CELL VIABILITY; CONTROLLED STUDY; DENTATE GYRUS; FEMALE; GENE EXPRESSION; HIPPOCAMPAL NEURONAL CULTURE; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MIDDLE AGED; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CYTOLOGY; DISEASE MODEL; GENETICS; HIPPOCAMPUS; METABOLISM; NERVE CELL; PATHOLOGY; SEVERITY OF ILLNESS INDEX; TRANSGENIC MOUSE;

ADULT; AGED; ANIMALS; APOPTOSIS; ASTROCYTES; CASPASE 3; CELLS, CULTURED; CYTOKINES; DENTATE GYRUS; DISEASE MODELS, ANIMAL; FEMALE; GLYCOGEN SYNTHASE KINASE 3 BETA; HIPPOCAMPUS; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, TRANSGENIC; MIDDLE AGED; NEURONS; OXIDATIVE STRESS; PROTEIN ISOFORMS; SEVERITY OF ILLNESS INDEX; TAU PROTEINS;

EID: 84986300521     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2016.104     Document Type: Article

References (73)

1. Vonsattel JP, DiFiglia M. Huntington's disease. J Neuropathol Exp Neurol 1998; 57: 369-384.
2. Ready RE, Mathews M, Leserman A, Paulsen JS. Patient and caregiver quality of life in Huntington's disease. Mov Disord 2008; 23: 721-726.
3. Novak MJ, Tabrizi SJ. A man with deteriorating ability to live independently. BMJ 2011; 24: 34.
4. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277: 1990-1993.
5. Cattaneo E, Rigamonti D, Goffredo D, Zucato C, Squitieri F, Sipione S. Loss of normal huntingtin function: new development in Huntington's disease research. Trends Neurosci 2001; 24: 182-188.
6. Hodges A, Strand AD, Arakagi AK, Kuhn A, Sengstag T, Huhes G et al. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Gen 2006; 15: 965-977.
7. Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, Tagle DA et al. Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum Mol Gen 2011; 20: 1438-1455.
8. Spargo E, Everall PI, Lantos PL. Neuronal loss in the hippocampus in Huntington's disease: a comparison with HIV infection. J Neurol Neurosurg Psychiatry 1993; 56: 487-491.
9. Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME et al. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 2003; 60: 1615-1620.
10. Ransome MI, Renoir T, Hannan AJ. Hippocampal neurogenesis, cognitive deficits and affective disorder in Huntington's disease. Neural Plast 2012; 2012: 874387.
11. Begeti F, Schwab LC, Mason SL, Barker RA. Hippocampal dysfunction defines disease onset in Huntington's disease. J Neurol Neurosurg Psychiatry 2016 (e-pub ahead of print; doi:10.1136/jnnp-2015-312413).
12. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-983.
13. Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 2005; 171: 1001-1012.
14. Bradford J, Shin JY, Roberts M, Wang CE, Li XJ, Li S. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci USA 2009; 106: 22480-22485.
15. Bradford J, Shin JY, Roberts M, Wang CE, Sheng G, Li S et al. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington's disease mice. J Biol Chem 2010; 285: 10653-10661.
16. Faideau M, Kim J, Cormier K, Gilmore R, Welch M, Auregan G et al. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. Hum Mol Gen 2010; 15: 3053-3067.
17. Hsiao HJ, Chen YC, Chen HM, Tu PH, Cern Y. A critical role of astrocyte-mediated nuclear factor-kB-dependent inflammation in Huntington's disease. Hum Mol Gen 2013; 22: 1826-1843.
18. Valenza M, Marullo M, Di Paolo E, Cesana E, Zuccato C, Biella G et al. Disruption of astrocyte-neuron cholesterol crosstalk affects neuronal function in Huntington's disease. Cell Death Differ 2015; 22: 690-702.
19. Fernandez-Nogales M, Cabrera JR, Santos-Galindo M, Hoozemans JJ, Ferrer I, Rozemuller AJ et al. Huntington's disease is a four-repeat tauopathy with tau nuclear rods. Nat Med 2014; 8: 881-885.
20. Blum D, Herrera F, Francelle L, Mendes T, Basquin M, Obriot H et al. Mutant huntingtin alters Tau phosphorylation and subcellular distribution. Hum Mol Gen 2015; 24: 76-85.
21. Gratuze M, Noël A, Julien C, Cisbani G, Milot-Rousseau P, Morin F et al. Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease. Hum Mol Gen 2015; 24: 86-99.
22. Vuono R, Winder-Rhodes S, de Sliva R, Cisbani G, Drouin-Ouellet J, REGISTRY Inversitigators of the European Huntington's Disease Network, et al. The role of tau in the pathological process and clinical expression of Huntington's disease. Brain 2015; 138: 1907-1918.
23. Gratuze M, Cisbani G, Cicchetti F, Planel E. Is Huntington's disease a tauopathy? Brain 2016; 139: 1014-1025.
24. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 1992; 147: 58-62.
25. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic mouse. EMBO J 2001; 20: 27-39.
26. Leroy K, Yilmaz Z, Brion JP. Increased level of active GSK-3b in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 2007; 33: 43-55.
27. Duka T, Duka V, Joyce JN, Sidhu A. α-Synuclein contributes to GSK-3β- catalyzed Tau phosphorylation in Parkinson's disease models. FASEB J 2009; 23: 2820-2830.
28. Sirerol-Piquer M, Gomez-Ramos P, Hernández F, Perez M, Morán MA, Fuster-Matanzo A et al. GSK3β overexpression induces neuronal death and a depletion of the neurogenic niches in the dentate gyrus. Hippocampus 2011; 21: 910-922.
29. Medina M, Wandosell F. Deconstructing GSK-3: the fine regulation of its activity. Int J Alzheimers Dis 2011; 2011: 479249.
30. Kaidanovich-Beilin O, Woodgett JR. GSK-3: functional insights from cell biology and animal models. Front Mol Neurosci 2011; 4: 40.
31. Duka V, Lee JH, Credle J, Wills J, Oaks A, Smolinsky C et al. Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases. PLoS One 2013; 8: e75025.
32. Llorens-Martín ML, Jurado J, Hernández F, Ávila J. GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci 2014; 21: 7-46.
33. Credle JJ, George JL, Wills J, Duka V, Shah K, Lee YC et al. GSK-3β dysregulation contributes to parkinson's-like pathophysiology with associated region-specific phosphorylation and accumulation of tau and α-synuclein. Cell Death Differ 2015; 22: 838-851.
34. Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase 3 beta (GSK3): Regulation, actions and diseases. Pharmacol Ther 2015; 148: 114-131.
35. Beurel E, Jope RS. Lypopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain. J Neuroinflammation 2009; 6: 9-19.
36. Beurel E, Michalek SM, Jope RS. Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3). Trends Immunol 2010; 31: 24-31.
37. Wang HM, Zhang T, Li Q, Huang JK, Chen RF, Sun XJ. Inhibition of glycogen synthase kinase-3β by lithium chloride suppresses 6-hydroxydopamine-induced inflammatory response in primary cultured astrocytes. Neurochem Int 2013; 63: 345-353.
38. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Cossetti C et al. Reactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Neurobiol Dis 2011; 41: 508-527.
39. L'Episcopo F, Serapide MF, Tirolo C, Testa N, Caniglia S, Morale MC et al. AWnt1 regulated Frizzled-1/β-catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: therapeutical relevance for neuron survival and neuroprotection. Mol Neurodegen 2011; 13: 6-49.
40. Valencia A, Reeves PB, Sapp E, Li X, Alexander J, Kegel KB et al. Mutant huntingtin and glycogen synthase kinase 3-beta accumulate in neuronal lipid rafts of a presymptomatic knock-in mouse model of Huntington's disease. J Neurosci Res 2010; 88: 179-190.
41. van Eyk CL, O'Keefe LV, Lawlor KT, Samaraweera SE, McLeod CJ, Price GR et al. Perturbation of the Akt/Gsk3-β signalling pathway is common to Drosophila expressing expanded untranslated CAG, CUG and AUUCU repeat RNAs. Hum Mol Gen 2011; 20: 783-2794.
42. Lejeune FX, Mesrob L, Parmentier F, Bicep C, Vazquez-Manrique RP, Parker JA et al. Large-scale functional RNAi screen in C. elegans identifies genes that regulate the dysfunction of mutant polyglutamine neurons. BMC Genomics 2012; 13: 91.
43. Carmichael J, Sugars KL, Bao YP, Rubinsztein DC. Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J Biol Chem 2002; 277: 33791-33798.
44. Berger Z, Ttofi EK, Michel CH, Pasco MY, Tenant S, Rubinsztein DC et al. Lithium rescues toxicity of aggregate-prone proteins in Drosophila by perturbing Wnt pathway. Hum Mol Gen 2005; 14: 3003-3011.
45. Scheuing L, Chiu CT, Liao HM, Linares GR, Chuang DM. Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned? Int J Biol Sci 2014; 10: 1024-1038.
46. Lim NK, Hung LW, Pang TY, Mclean CA, Liddell JR, Hilton JB et al. Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain. Hum Mol Gen 2014; 23: 4051-4063.
47. Fernández-Nogales M, Hernández F, Miguez A, Alberch J, Ginés S, Pérez-Navarro E et al. Decreased glycogen synthase kinase-3 levels and activity contribute to Huntington's disease. Hum Mol Gen 2015; 24: 5040-5042.
48. Chen G, Bower KA, Ma C, Fang S, Thiele CJ, Luo J. Glycogen synthase kinase 3β (GSK3β) mediates 6-hydroxy dopamine-induced neuronal death. FASEB J 2004; 18: 1162-1164.
49. Petit-Paitel A, Brau F, Cazareth J, Chabry J. Involment of cytosolic and mitochondrial GSK-3beta in mitochondrial dysfunction and neuronal cell death of MPTP/MPP+- treated neurons. PLoS One 2009; 4: e5491.
50. Hongo H, Kihara T, Kume T, Izumi Y, Niidome T, Sugimoto H et al. Glycogen synthase kinase-3β activation mediates rotenone-induced cytotoxicity with the involvement of microtubule destabilization. Biochem Biophys Res Commun 2012; 426: 94-99.
51. Cole A, Frame S, Cohen P. Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3 (GSK3) in mammalian cells is an autophosphorylation event. Biochem J 2004; 377: 249-255.
52. Lochhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N, Cleghon V. A chaperonedependent GSK3beta transitional intermediate mediates activation loop autophosphorylation. Mol Cell 2006; 24: 627-633.
53. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559-577.
54. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
55. Andersen C, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004; 64: 5245-5250.
56. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acid Res 2002; 30: e36.
57. Li X, Friedman AB, Ro MS, Jope RS. Anesthesia and post-mortem interval profoundly influences the regulatory serine phophorylation of glycogen synthase kinase-3 in mouse brain. J Neurochem 2005; 92: 701-704.
58. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87: 493-506.
59. Valencia A, Sapp E, Reeves PB, Alexander J, Masso N, Li X et al. Reagents that block neuronal death from Huntington's disease also curb oxidative stress. Neuroreport 2012; 23: 10-15.
60. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Impagnatiello F et al. Aging-induced Nrf2-ARE pathway disruption in the subventricular zone drives neurogenic impairment in parkinsonian mice via PI3K-Wnt/β-catenin dysregulation. J Neurosci 2013; 33: 1462-1485.
61. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Deleidi M et al. Plasticity of subventricular zone neuroprogenitors in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease involves crosstalk between inflammatory and Wnt/β-catenin signaling pathways: functional consequences for neuroprotection and repair. J Neurosci 2012; 32: 2062-2085.
62. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Marchetti B. Glia as a turning point in the therapeutic strategy of Parkinson's disease. CNS Neurol Disord 2010; 9: 349-372.
63. Marchetti B, L'Episcopo F, Morale MC, Tirolo C, Testa N, Caniglia S et al. Uncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: The Wnt/ß-catenin signaling cascade as the common final pathway for neuroprotection and self-repair. Eur J Neurosci 2013; 37: 1550-1563.
64. Garwood CJ, Pooler AM, Atherton J, Hanger DP, Noble W. Astrocytes are important mediators of Aβ-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis 2011; 2: e167.
65. Marchetti B, Pluchino S. Wnt your brain be inflamed? Yes, it Wnt! Trends Mol Med 2013; 19: 144-156.
66. Tunbridge EM, Eastwood SL, Harrison PJ. Changed relative to what? Housekeeping genes and normalization strategies in human brain gene expression studies. Biol Psychiatry 2011; 69: 173-179.
67. Drouin-Ouellet J, Sawiak SJ, Cisbani G, Lagacé M, Kuan WL, Saint-Pierre M et al. Cerebrovascular and blood-brain barrier impairments in Huntington's disease: potential implications for the pathophysiology. Ann Neurol 2015; 78: 160-177.
68. Cicchetti F, Lacroix S, Cisbani G, Vallières N, Saint-Pierre M, St-Amour I et al. Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol 2014; 76: 31-42.
69. Gennuso F, Fernetti C, Tirolo C, Testa N, L'Episcopo F, Caniglia S et al. Bilirubin protects astrocytes from its own toxicity inducing up-regulation and translocation of multigrug resistance-associated protein 1 (Mrp 1). Proc Natl Acad Sci USA 2004; 101: 2470-2475.
70. Senatorov VV, Ren M, Kanai H, Wei H, Chuang DM. Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease. Mol Psychiatry 2004; 9: 371-385.
71. Gallo F, Morale MC, Spina-Purrello V, Tirolo C, Testa N, Farinella Z et al. Basic fibroblast growth factor (bFGF) acts on both neurons and glia to mediate the neurotrophic effects of astrocytes on LHRH neurons in culture. Synapse 2000; 36: 233-253.
72. L'Episcopo F, Tirolo C, Testa N, Caniglia S, Morale MC, Impagnatiello F et al. Switching the microglial harmful phenotype promotes lifelong restoration of substantia nigra dopaminergic neurons from inflammatory neurodegeneration in aged mice. Rejuvenation Res 2011; 14: 411-424.
73. Bhat R, Xue Y, Berg S, Helberg S, Ormo M, Nilsson Y et al. Structural insight and biological effect of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem 2003; 278: 45937-4945.